Although NK cells, which are classified within the broader ILC family, have been extensively studied as targets for adoptive cell therapy, with significant progress in ex vivo expansion, differentiation from pluripotent stem cells, and CAR-NK engineering for cancer treatment, the therapeutic development of helper ILC subsets (ILC1, ILC2, ILC3, and LTi cells) remains comparatively underexplored. The gene discussed is CCL27; the disease is cancer.